Mangoceuticals Reports 336% Sales Growth for $99 Monthly Testosterone Therapy Program

Mangoceuticals, operating under the MangoRx and PeachesRx brands, has reported significant initial success for its recently launched all-inclusive injectable testosterone replacement therapy program priced at $99 per month. The comprehensive program includes doctor visits, consultations, lab work and prescribed medication, providing a complete telehealth solution for hormone health management. Since launching in mid-December, month-over-month sales of the injectable TRT program have increased 336% while customer acquisition costs declined 54%, reflecting what the company described as growing demand for convenient hormone health solutions delivered through its telehealth platform.

The company expects TRT to serve as a primary growth driver as it seeks to expand its presence in the global TRT market, estimated at approximately $2.1 billion to $2.2 billion in 2025. This expansion strategy includes oral formulations such as PRIME by MangoRx powered by Kyzatrex, complementing the injectable program to offer multiple treatment options. The company's approach leverages its secure telemedicine platform to provide pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management.

MangoRx's business model allows interested consumers to use the telemedicine platform for a smooth experience where prescription requests are reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx's partner compounding pharmacy directly to the patient's doorstep. This integrated approach addresses multiple aspects of men's health and wellness through a single platform, potentially reducing barriers to treatment access. The company's focus on developing a variety of men's health products and services positions it within a growing telehealth market segment that has gained increased attention and adoption in recent years.

The reported sales growth and reduced customer acquisition costs suggest that the $99 monthly pricing model resonates with consumers seeking affordable hormone replacement therapy options. This pricing strategy, combined with the all-inclusive nature of the program that eliminates additional costs for doctor visits and lab work, represents a competitive approach in the TRT market. The company's success with this program may influence how other telehealth providers structure their hormone therapy offerings and pricing models moving forward.

For more information about MangoRx's mission and other products, please visit https://www.MangoRx.com. Additional details about the company's communications platform and services can be found at https://www.MissionIR.com, which provides specialized communications services within the investment community through its Dynamic Brand Portfolio. The platform delivers access to wire solutions, article and editorial syndication to thousands of outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions designed to increase visibility for private and public companies.